-
Malawi's fuel shortages, record prices deepen economic crisis
-
Shock, vindication, regret: Scientists react to AI roiling life's work
-
The Duskbloods delayed as Nintendo Switch 2 release moves to 2027
-
Britain's King Charles lands in ex-colony Guyana
-
Tech firms take fresh hit as earnings misses fan AI fears
-
Dodging fuel price hikes, Damascus drivers turn to electric cars
-
Nvidia's web of AI bets: smart strategy or bubble risk?
-
Lethbridge students learn how city transit and transportation systems work
-
DoorDash shares rise as Instacart slips following $17 billion takeover plan
-
Horoscope for October 30, 2026: communication and patience shape the day
-
Amazon cloud business accelerates but shares drop on profit miss
-
Inkle buys Finally bookkeeping unit and expands India-based workforce
-
PI Industries plans Indian launch of Pioxaniliprole insecticide this rabi season
-
ISRO schedules NVS-03 navigation satellite launch for Friday
-
Asian equities diverge after mixed technology earnings and Fed rate decision
-
'Star Trek', 'X-Men' star Patrick Stewart dead at 86
-
Kuwait traffic authority cautions against hazard lights while driving in rain
-
Canada buying stake in AI firm Cohere to bolster tech sovereignty
-
Utah files criminal charges against prediction market Kalshi
-
Grieving Spain demands answers for latest rail disaster
-
Kuwait National Guard official visits member injured during training
-
Qatar prime minister tours Cityscape Qatar 2026
-
CNN Global Perspectives prepares Doha debut with international speaker lineup
-
Jazeera Paints showcases housing solutions at Build Your House 2026 in Qatar
-
Es’hailSat and Arabsat agree broader satellite and broadcasting cooperation
-
Google drags down Wall Street stocks
-
ECB says has tools to calm markets as French debt worries rise
-
Does White House ask AI to shape policy? Democrats want the receipts
-
IMF says engaging with Iraq on preparing new bailout program
-
ECB holds rates steady after Lagarde says to quit early
-
US economy posts strong growth, inflation stubbornly high in challenge to Trump
-
ECB chief Lagarde to step down early, triggering succession race
-
French businessman takes over 2030 Winter Olympics amid leadership turmoil
-
VW says 'no time to lose' to slash costs after 5.8 billion euro loss
-
Stock markets diverge on corporate earnings, tech jitters
-
Oil majors reap bumper profits as Mideast war drives prices
-
TotalEnergies profit hits record on high oil prices
-
Taiwan says Pakistan briefly closed airspace to Taiwanese flights
Embattled Philips says respirators 'within safety limits'
Under-fire Dutch medical device maker Philips said Wednesday extensive testing on its recalled respirator devices showed they were "within safety limits" for use, but that a final verdict rests with global regulatory authorities.
The Amsterdam-based company announced a global recall of its appliances to treat people suffering from sleep apnoea 18 months ago over concerns patients risked "possible toxic and carcinogenic effects" if they inhaled or swallowed pieces of degraded sound-dampening foam on the machines.
The recall has so far cost the company 2.2 billion euros ($2.3 billion), pushed it to cut 4,000 jobs and seen one chief executive step down.
But the company announced on Wednesday that extensive testing showed the respirators were "compliant with... allowable limits for particle matter emissions."
Philips based its results on research done by five independent laboratories, third party experts as well as an external medical panel, it said.
The research found exposure to particle matter emissions from degraded foam "is unlikely to result in an appreciable harm to health in patients," Philips said.
"Today is important because it starts with reassuring that the product that we did put out actually was within the safety limits," Philips' chief executive Roy Jakobs told AFP.
- 'FDA is still considering' -
"This is a complex matter and we wanted to do a very scientific, thorough job," he added.
The latest test results have now been submitted to regulatory authorities including the US Food and Drug Administration, which still need to make an assessment.
"The FDA is still considering the data and analyses... provided and may reach different conclusions," Philips said.
Philips also noted that its advice to patients remains unchanged: consult with their doctor to consider whether to continue to use the affected models, or switch to a different model or alternative treatments.
It said was continuing to test other models, including ones with a different type of foam.
It is also looking at the impact of non-regulatory approved cleaning methods on the machines, saying data available so far showed ozone cleaning to have exacerbated foam degradation.
Investors responded positively to Philips' announcement, with its share price jumping by over four percent in midday trade on the Amsterdam stock exchange's blue-chip AEX index.
Starting off as a lighting company more than 130 years ago, Philips has undergone major changes in recent years, selling off assets to focus on making high-end electronic healthcare products.
D.Goldberg--CPN